Arrowhead Pharmaceuticals (ARWR) FCF Margin (2010 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 17 years of FCF Margin data on file, last reported at 111.04% in Q1 2026.

• Quarterly FCF Margin rose 2816.0% year-over-year to 111.04% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 4.58% (down 634.0% YoY) and the FY2025 annual result came in at 21.61%, up 1703992.0% from the prior year.
• FCF Margin improved to 111.04% in Q1 2026, from 4.29% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 188.46% in Q2 2023 to a low of 5953.84% in Q4 2024.
• A 5-year average of 945.25% and a median of 111.64% in 2022 frame the typical range for FCF Margin.
• Annual changes were most pronounced in 2023 — FCF Margin slumped 506898 bps — and 2025, when it soared 595813 bps.
• Tracing ARWR's FCF Margin over 5 years: stood at 182.95% in 2022, then sank by 2771 bps to 5251.93% in 2023, then dropped by 13 bps to 5953.84% in 2024, then jumped by 100 bps to 4.29% in 2025, then soared by 2487 bps to 111.04% in 2026.
• The last three FCF Margin figures came in at 111.04% (Q1 2026), 4.29% (Q4 2025), and 8.02% (Q3 2025), per Business Quant data.